| Literature DB >> 28432800 |
Xuehai Pang1,2, Lingling Peng3, Yuanwei Chen1,2,3,4.
Abstract
Enzalutamide, a second-generation antiandrogen, has been developed for the treatment of castration-resistance prostate cancer. We synthesized the deuterated analogues 6 and found that it showed higher drug exposure and thus stronger antitumor potency in preclinical settings. Compound 6 is being developed clinically for the potential to be differentiated from enzalutamide through reduced dosages and a higher safety margin.Entities:
Keywords: CRPC; LNCaP/AR xenograft; PK/PD; deuterated drug; enzalutamide
Mesh：
Substances：
Year: 2017 PMID： 28432800 DOI： 10.1002/jlcr.3516
Source DB: PubMed Journal: J Labelled Comp Radiopharm ISSN： 0362-4803 Impact factor: 1.921